MetaCap

AN2 Therapeutics (ANTX) vs Bicycle Therapeutics (BCYC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed Bicycle Therapeutics (BCYC) over the past year, gaining 366.1% versus a loss of 54.1%. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $192.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%BCYC-54.11%
+503%+211%-81%
Nov 21, 20251 yearNov 20, 2026
ANTX-67.01%BCYC-93.13%
+42%-29%-100%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus BCYC key metrics
MetricANTXBCYC
Share price$5.08$2.90
Market cap$192.75M$203.27M
1-day change-2.68%-4.92%
YTD return+345.61%-59.04%
1-year return+366.06%-54.11%
5-year return—-94.69%
EPS (TTM)$-0.91$-2.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$72.59M
Revenue growth (YoY)—+105.77%
Net income (latest FY)$-35.17M$-218.96M
Operating margin—-340.38%
Net margin—-301.66%
52-week high$7.19$7.83
52-week low$1.00$2.85
Distance from 52-week high-29.35%-62.96%
Analyst consensusstrong_buybuy
Avg. price target upside+77.17%+216.21%
Average volume289.29K444.72K
Shares outstanding37.94M50.66M
Employees21288
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed BCYC by 420.2 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Bicycle Therapeutics

BCYC stock →

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.

Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees

ANTX vs BCYC FAQ

Which is bigger, AN2 Therapeutics or Bicycle Therapeutics?

Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $192.75M for AN2 Therapeutics (ANTX).

Which stock has performed better over the past year, ANTX or BCYC?

ANTX returned +366.06% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and Bicycle Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons